Browse

CYP3A5*1 Allele: Impacts on Early Acute Rejection and Graft Function in Tacrolimus-Based Renal Transplant Recipients

DC Field Value Language
dc.contributor.authorMin, Sang-Il-
dc.contributor.authorKim, Seong Yup-
dc.contributor.authorAhn, Sang Hyun-
dc.contributor.authorMin, Seung-Kee-
dc.contributor.authorKim, Yon Su-
dc.contributor.authorOh, Jung Mi-
dc.contributor.authorHa, Jongwon-
dc.contributor.authorKim, Sang Joon-
dc.contributor.authorMoon, Kyung Chul-
dc.contributor.authorKim, Si Hwa-
dc.date.accessioned2012-06-28T02:01:44Z-
dc.date.available2012-06-28T02:01:44Z-
dc.date.issued2010-12-27-
dc.identifier.citationTRANSPLANTATION; Vol.90 12; 1394-1400ko_KR
dc.identifier.issn0041-1337-
dc.identifier.urihttp://hdl.handle.net/10371/77721-
dc.description.abstractBackground. Tacrolimus is a major immunosuppressant, which has a narrow therapeutic range and wide interindividual variation. The effects of genetic polymorphisms of cytochrome P450 3A (CYP3A) 5 and Adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) genes on the achievement of target tacrolimus trough levels and clinical outcomes in renal transplants were evaluated. Methods. A total of 62 patients participated in this prospective study. After an initial fixed oral dose (0.08 mg/kg two times per day), tacrolimus doses were adjusted to a target range based on daily measurement of blood trough concentration. Every patient underwent 10-day scheduled biopsy. Both the patients and investigators were blinded for the genetic polymorphisms. Results. Those subjects expressing CYP3A5 (n = 29) evidenced significantly lower tacrolimus trough levels between days 1 and 5 after transplantation, when compared with nonexpressers (n = 33). Significantly higher overall incidences of early T-cell-mediated rejection (TCR) of at least Banff grade 1 inseverity (P = 0.017), including clinical rejection within 10 days and subclinical rejection in biopsies at postoperative day 10 were detected in CYP3A5 expressers. The severity of TCR according to Banff`07 classification was associated with CYP3A5 genotypes (P = 0.012). Moreover, multivariate analysis identified CYP3A5 expression as an independent risk factor for TCR (odds ratio: 2.79; P = 0.043). Significantly lower estimated glomerular filtration rates until 1 month and numerically lower estimated glomerular filtration rates by 12 months were noted in the CYP3A5 expressers. The genetic polymorphisms of the ABCB1 genes exerted no significant effects. Conclusion. We confirmed the significant effects of CYP3A5 polymorphism on the achievement of target tacrolimus trough levels and the development of acute rejection in early period after transplantation and consequent renal allograft function.ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectCYP3A5ko_KR
dc.subjectAcute rejectionko_KR
dc.subjectTacrolimusko_KR
dc.subjectRenal transplantationko_KR
dc.subjectPharmacogeneticsko_KR
dc.titleCYP3A5*1 Allele: Impacts on Early Acute Rejection and Graft Function in Tacrolimus-Based Renal Transplant Recipientsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor민상일-
dc.contributor.AlternativeAuthor김성엽-
dc.contributor.AlternativeAuthor안상현-
dc.contributor.AlternativeAuthor민승기-
dc.contributor.AlternativeAuthor김시화-
dc.contributor.AlternativeAuthor김연수-
dc.contributor.AlternativeAuthor문경철-
dc.contributor.AlternativeAuthor오정미-
dc.contributor.AlternativeAuthor김상준-
dc.contributor.AlternativeAuthor하종원-
dc.identifier.doi10.1097/TP.0b013e3181fa93a4-
dc.citation.journaltitleTRANSPLANTATION-
dc.description.citedreferenceMusuamba FT, 2009, THER DRUG MONIT, V31, P734-
dc.description.citedreferenceKainz A, 2009, TRANSPLANTATION, V88, P1095, DOI 10.1097/TP.0b013e3181bb25f1-
dc.description.citedreferenceBorobia AM, 2009, THER DRUG MONIT, V31, P436-
dc.description.citedreferenceSatoh S, 2009, EUR J CLIN PHARMACOL, V65, P473, DOI 10.1007/s00228-008-0606-3-
dc.description.citedreferenceJun KR, 2009, TRANSPLANTATION, V87, P1225, DOI 10.1097/TP.0b013e31819f117e-
dc.description.citedreferencePress RR, 2009, THER DRUG MONIT, V31, P187-
dc.description.citedreferenceBandur S, 2008, TRANSPLANTATION, V86, P1206, DOI 10.1097/TP.0b013e318187c4d1-
dc.description.citedreferenceSolez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x-
dc.description.citedreferenceHesselink DA, 2008, PHARMACOGENET GENOM, V18, P339-
dc.description.citedreferenceMacPhee IAM, 2008, TRANSPLANTATION, V85, P163, DOI 10.1097/TP.0b013e3181609054-
dc.description.citedreferenceStaatz C, 2001, NEPHROL DIAL TRANSPL, V16, P1905-
dc.description.citedreferenceKuehl P, 2001, NAT GENET, V27, P383-
dc.description.citedreferenceChristians U, 2002, CLIN PHARMACOKINET, V41, P813-
dc.description.citedreferenceChoi JH, 2007, BRIT J CLIN PHARMACO, V64, P185, DOI 10.1111/j.1365-2125.2007.02874.x-
dc.description.citedreferenceHaufroid V, 2006, AM J TRANSPLANT, V6, P2706, DOI 10.1111/j.1600-6143.2006.01518.x-
dc.description.citedreferenceYu SF, 2006, TRANSPLANTATION, V81, P46, DOI 10.1097/01.tp.00000188118.34633.bf-
dc.description.citedreferenceMEIERKRIESCHE H, 2006, AM J TRANSPLANT, V6, P1994-
dc.description.citedreferenceMacPhee IAM, 2005, TRANSPLANTATION, V79, P499, DOI 10.1097/01.TP.0000151766.73249.12-
dc.description.citedreferenceTsuchiya N, 2004, TRANSPLANTATION, V78, P1182, DOI 10.1097/01.TP.0000137789.58694.B4-
dc.description.citedreferenceZahir H, 2004, THER DRUG MONIT, V26, P506-
dc.description.citedreferenceMacPhee IAM, 2004, AM J TRANSPLANT, V4, P914, DOI 10.1111/j.1600-6143.2004.00435.x-
dc.description.citedreferenceStaatz CE, 2004, CLIN PHARMACOKINET, V43, P623-
dc.description.citedreferenceThervet E, 2003, TRANSPLANTATION, V76, P1233, DOI 10.1097/01.TP.0000090753.99170.89-
dc.description.citedreferenceMacphee IAM, 2002, TRANSPLANTATION, V74, P1486, DOI 10.1097/01.TP.0000045761.71385.9F-
dc.description.citedreferenceHebert MF, 1997, ADV DRUG DELIVER REV, V27, P201-
dc.description.citedreferenceEvans WE, 1999, SCIENCE, V286, P487-
dc.description.citedreferenceUndre NA, 1999, TRANSPLANT P, V31, P296-
dc.description.citedreferenceChow FS, 1997, DRUG METAB DISPOS, V25, P610-
dc.description.citedreferenceLampen A, 1995, DRUG METAB DISPOS, V23, P1315-
dc.description.citedreferenceKNIEPEISS D, CLIN TRANSP IN PRESS-
dc.description.tc2-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse